Stockreport

JNJ Inks Licensing Deal With Kaken for Eczema Candidate KP-723 [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF Pharmaceutical to develop, manufacture and commercialize the latter's STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD). The licensing [Read more]